Feed/Investors/Hengdian Group Capital

Hengdian Group Capital

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on one round in the feed.

Since 2026-01-22

ROUNDS

joined, none as lead

ROUNDS JOINED · USD

$287M

across 1 round

LATEST ROUND

Series D+ · $287M · 2026-01-22

CO-INVESTORS

named beside it

Rounds

[ 1 ]

The rounds this investor is named on, who it invests beside, and where it shows up.

Company	Round	Amount	Announced	Role
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus.	Series D+ Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$287M	2026-01-22	[ PART ]